GoodRx Holdings, Inc. (GDRX) Class Action Lawsuit (April 2024)

Closed

2:24cv3282 • April 22, 2024

Class Period Start

September 23, 2020

Class Period End

November 8, 2022

PSLRA Deadline

June 21, 2024

Case Allegations

10b5

Statutes of Repose

Sep 23, 2023

Country

United States

Court

Federal Court

Docket History

Apr 18, 2025

Motion to Dismiss Granted (opens in a new tab)

The court has granted the defendants' request to dismiss the lawsuit. Depending on the court's decision, the plaintiffs may be allowed to file an updated complaint or pursue an appeal.

Jan 24, 2025

Second Amended Complaint (opens in a new tab)

A new complaint has been filed on behalf of certain investors in GoodRx Holdings, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Nov 19, 2024

Motion to Dismiss (opens in a new tab)

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

Sep 20, 2024

First Amended Complaint (opens in a new tab)

A new complaint has been filed on behalf of certain investors in GoodRx Holdings, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Jul 23, 2024

Appointment of Lead Plaintiff (opens in a new tab)

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Apr 22, 2024

First Filed Complaint (opens in a new tab)

A securities fraud class action complaint has been filed on behalf of certain investors in GoodRx Holdings, Inc..